Detection and differential diagnosis of colon cancer by a cumulative analysis of promoter methylation

Nature Communications

Volumn 3, Issue , 2012, Pages

  Yang, Qiong ^a   Dong, Ying ^b   Wu, Wei ^a   Zhu, Chunlei ^a   Chong, Hui ^a   Lu, Jiangyang ^b   Yu, Dehai ^a   Liu, Libing ^a   Lv, Fengting ^a   Wang, Shu ^a  

^a INSTITUTE OF CHEMISTRY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMER;

ACCURACY ASSESSMENT; BIOMARKER; CANCER; DISCRIMINANT ANALYSIS; ENERGY; FLUORESCENCE; METHYLATION; POLYMER;

AGED; APC GENE; ARTICLE; CANCER DIAGNOSIS; CDKN2A GENE; CHINESE; COLON ADENOMA; COLON CANCER; COLON CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISCRIMINANT ANALYSIS; DNA METHYLATION; ESR1 GENE; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MGMT GENE; MLH1 GENE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROMOTER REGION; SENSITIVITY AND SPECIFICITY; TMEFF2 GENE; VIM GENE;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; CATIONS; COLONIC NEOPLASMS; CPG ISLANDS; DIAGNOSIS, DIFFERENTIAL; DNA; DNA METHYLATION; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENES, NEOPLASM; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLYMERS; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84870776420     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms2209     Document Type: Article

References (36)

1. Lao, V. V. & Grady, W. M. Epigenetics and colorectal cancer. Nat. Rev. Gastroenterol. Hepatol. 18, 686-700 (2011).
2. Ogino, S., Chan, A. T., Fuchs, C. S. & Giovannucci, E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 60, 397-411 (2011).
3. Carmona, F. J. & Esteller, M. Epigenomics of human colon cancer. Mutat. Res. 693, 53-60 (2010).
4. Shima, K. et al. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers. PLoS One 6, e25062 (2011).
5. Kim, M. S., Lee, J. & Sidransky, D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev. 29, 181-206 (2010).
6. Hughes, L. A. et al. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim. Biophys. Acta 1825, 77-85 (2012).
7. Shirahata, A. et al. Vimentin methylation as a marker for advanced colorectal carcinoma. Anticancer Res. 29, 279-281 (2009).
8. Chen, W. D. et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J. Natl Cancer Inst. 97, 1124-1132 (2005).
9. Ned, R. M., Melillo, S. & Marrone, M. Fecal DNA testing for colorectal cancer screening: the ColoSuret test. PLoS Curr. 3, RRN1220 (2011).
10. Zheng, S. L. et al. Cumulative association of five genetic variants with prostate cancer. N. Engl. J. Med. 358, 910-919 (2008).
11. Papageorgiou, E. A. et al. Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21. Nat. Med. 17, 510-513 (2011).
12. Thomas, S. W., Joly, G. D. & Swager, T. M. Chemical sensors based on amplifying fluorescent conjugated polymers. Chem. Rev. 107, 1339-1386 (2007).
13. Ho, H. A., Najari, A. & Leclerc, M. Optical detection of DNA and proteins with cationic polythiophenes. Acc. Chem. Res. 41, 168-178 (2008).
14. Gaylord, B. S., Heeger, A. J. & Bazan, G. C. DNA hybridization detection with water-soluble conjugated polymers and chromophore-labeled single-stranded DNA. J. Am. Chem. Soc. 125, 896-900 (2003).
15. Duan, X., Liu, L., Feng, F. & Wang, S. Cationic conjugated polymers for optical detection of DNA methylation, lesions and single nucleotide polymorphisms. Acc. Chem. Res. 43, 260-270 (2010).
16. Feng, F., Liu, L. & Wang, S. Fluorescent conjugated polymer-based FRET technique for detection of DNA methylation of cancer cells. Nat. Protoc. 5, 1255-1264 (2010).
17. Singer-Sam, J., LeBon, J. M., Tanguay, R. L. & Riggs, A. D. A quantitative HpaII-PCR assay to measure methylation of DNA from a small number of cells. Nucleic Acids Res. 18, 687-692 (1990).
18. Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D. & Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93, 9821-9826 (1996).
19. Gonzalgo, M. L. & Jones, P. A. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). Nucleic Acids Res. 25, 2529-2531 (1997).
20. Xiong, Z. & Laird, P. W. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 25, 2532-2534 (1997).
21. Hayatsu, H. The bisulfite genomic sequencing used in the analysis of epigenetic states, a technique in the emerging environmental genotoxicology research. Mutat. Res. 659, 77-82 (2008).
22. Grady, W. M., Rajput, A., Lutterbaugh, J. D. & Markowitz, S. D. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res. 61, 900-902 (2001).
23. Goto, T. et al. Aberrant methylation of the p16 gene is frequently detected in advanced colorectal cancer. Anticancer Res. 29, 275-277 (2009).
24. Petko, Z. et al. Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin. Cancer Res. 11, 1203-1209 (2005).
25. Kane, M. F. et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 57, 808-811 (1997).
26. Lee, S. et al. Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab. Invest. 84, 884-893 (2004).
27. Bariol, C. et al. The relationship between hypomethylation and CpG island methylation in colorectal neoplasia. Am. J. Pathol. 162, 1361-1371 (2003).
28. Curtin, K., Slattery, M. L. & Samowitz, W. S. CpG island methylation in colorectal cancer: past, present and future. Pathol. Res. Int. 12, 902674 (2011).
29. Hinoue, T. et al. The role of the CpG island methylator phenotype in colorectal cancer. Genome Res. 22, 271-282 (2012).
30. Dahlin, A. M. et al. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin. Cancer Res. 16, 1845-1855 (2010).
31. Ogino, S. et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58, 90-96 (2009).
32. Ogino, S., Kawasaki, T., Kirkner, G. J., Loda, M. & Fuchs, C. S. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J. Mol. Diagn. 8, 582-588 (2006).
33. Yamauchi, M. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 61, 847-854 (2012).
34. Tjalsma, H., Boleij, A., Marchesi, J. R. & Dutilh, B. E. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat. Rev. Microbiol. 10, 575-582 (2012).
35. Stein, R. A. Epigenetics-the link between infectious diseases and cancer. JAMA 305, 1484-1485 (2011).
36. Iacopetta, B., Kawakami, K. & Watanabe, T. Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup? Int. J. Clin. Oncol. 13, 498-503 (2008).